Compare Matson Inc (MATX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Matson Inc trades at $237.82 (market cap $7.03B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Matson Inc is far larger — about 7.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Matson Inc pays a 0.65% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 25 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MATX | MRVI | |
|---|---|---|
Market Cap | $7.03B | $972.90M |
Volume | 327,630 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $238.60 | $9.00 |
52-Week Low | $93.22 | $2.83 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $7.63B | $1.08B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $235.22, up 3.31% with strong bullish momentum supported by consistent earnings beats and positive technical indicators. The stock shows robust fundamentals with a 13.41% net income margin and 17.21% ROE, while valuation metrics remain reasonable with a P/E of 15.87. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 expected, driving positive sentiment.
Outlook remains positive with Wall Street analysts projecting 27.3% upside potential and strong institutional buying activity. Key risks include freight market volatility and competitive pressures, but the company's raised full-year guidance and dividend payments provide stability for investors seeking transportation sector exposure.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
